| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/27/2001 | WO2001017558A3 Novel uses of mammalian ccr6 receptors and related reagents |
| 09/27/2001 | WO2001017547A3 Bmp-9 compositions and methods for inducing differentiation of cholinergic neurons |
| 09/27/2001 | WO2001013895A3 Controlled-release sedative-hypnotic compositions and methods related thereto |
| 09/27/2001 | WO2001012606B1 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 09/27/2001 | WO2001009178A3 Human chaperone proteins |
| 09/27/2001 | WO2001000665A3 Inhibitors of memapsin 2 and use thereof |
| 09/27/2001 | WO2000074664A3 Novel iron chelators and pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders |
| 09/27/2001 | WO2000061541A3 Pharmaceutical compounds |
| 09/27/2001 | WO2000059489A8 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 09/27/2001 | US20010025057 Containing nitric oxide donar containing nitroglycerin, glycol dinitrate, isopropyl nitrate, glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, butane-1,2,4-triol-trinitrate, erythrityl teteranitrate, pentaerithrityl tetetranitrate etc. |
| 09/27/2001 | US20010025044 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 09/27/2001 | US20010025042 A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders |
| 09/27/2001 | US20010025039 Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity |
| 09/27/2001 | US20010025036 Modifying the structure of a 1alpha-hydroxylated vitamin D compound to increase its in vivo activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents 1alphahydroxy in axial orientation |
| 09/27/2001 | US20010025035 Water soluble prodrugs of hindered alcohols |
| 09/27/2001 | US20010025030 cDNA for human methylenetetrahydrofolate reductase and uses thereof |
| 09/27/2001 | US20010024827 Which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells; for treatment of neuronal disorders |
| 09/27/2001 | US20010024813 Human dendriac and brainiac-3 |
| 09/27/2001 | US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024642 A chewing gum that includes a gum center and a coating that substantially surrounds the center, comprises at least 50% by weight of chewing gum, the coating includes medicine; chewing the gum, causes the drug release, in patients buccal cavity |
| 09/27/2001 | DE10050268A1 Dentifrice composition containing hypnotic-sedative agent, to aid sleep in addition to cleaning the teeth |
| 09/27/2001 | DE10013712A1 Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung Nicotine salts with improved taste, process for their preparation and their use |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2404115A1 The use of peg-hirudin as an anticoagulant agent in the extracorporeal treatment of blood |
| 09/27/2001 | CA2404076A1 Heterocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | CA2403828A1 Inhibitors of p38 |
| 09/27/2001 | CA2403823A1 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403805A1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | CA2403714A1 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 09/27/2001 | CA2403681A1 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | CA2403553A1 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | CA2403447A1 Peptide derivative |
| 09/27/2001 | CA2403436A1 Acute neuronal induced calcium binding protein type 1 ligand |
| 09/27/2001 | CA2402836A1 Process for preparing crystalline form i of cabergoline |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402747A1 G-protein associated molecules |
| 09/27/2001 | CA2402414A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401984A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401908A1 Amorphous torasemide modification |
| 09/27/2001 | CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha. |
| 09/27/2001 | CA2401749A1 Compounds and methods to treat alzheimer's disease |
| 09/27/2001 | CA2401728A1 Difluorobutyric acid metalloprotease inhibitors |
| 09/27/2001 | CA2400637A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | CA2399991A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
| 09/27/2001 | CA2399985A1 Compounds with 5-ht activity useful for controlling visual field loss |
| 09/27/2001 | CA2383848A1 Diagnosis of a person's risk of developing alcoholism |
| 09/27/2001 | CA2374073A1 Novel polypeptides and nucleic acids encoding same |
| 09/27/2001 | CA2364268A1 Di-substituted iminoheterocyclic compounds |
| 09/26/2001 | EP1136571A2 Detection of polymorphisms in the MxA gene to predict the response of an hepatitis C virus infected individual to interferon therapy |
| 09/26/2001 | EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/26/2001 | EP1136503A1 Novel physiologically active substance, process for producing the same and utilization thereof |
| 09/26/2001 | EP1136493A1 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives |
| 09/26/2001 | EP1136491A1 2-[(Heteroaryl)alkylamino]pyrimidone derivatives |
| 09/26/2001 | EP1136490A1 New forms of paroxetin hydrochloride |
| 09/26/2001 | EP1136489A1 2-[Piperidin-1-yl]pyrimidone derivatives |
| 09/26/2001 | EP1136487A1 Nicotine salts with improved taste, process for their preparation and use thereof as smoking cessation agents |
| 09/26/2001 | EP1136486A1 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives |
| 09/26/2001 | EP1136485A1 Aminophenyl pyrimidone derivatives |
| 09/26/2001 | EP1136484A1 2-(Arylalkylamino)pyrimidone derivatives |
| 09/26/2001 | EP1136483A1 2-[Piperazinyl]pyrimidone derivatives |
| 09/26/2001 | EP1136482A1 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| 09/26/2001 | EP1136477A1 Benzofuran derivatives, process for the preparation of the same and uses thereof |
| 09/26/2001 | EP1136475A1 Piperidine and piperazine compounds for use in the treatment of Alzheimer |
| 09/26/2001 | EP1136099A1 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
| 09/26/2001 | EP1135519A1 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 09/26/2001 | EP1135513A1 Adenovirus-mediated gene therapy |
| 09/26/2001 | EP1135496A2 Ucp5 |
| 09/26/2001 | EP1135494A2 Neuron-associated proteins |
| 09/26/2001 | EP1135490A1 Human vanilloid receptors and their uses |
| 09/26/2001 | EP1135484A2 Gtpase associated proteins |
| 09/26/2001 | EP1135468A1 Virus vectors and methods of making and administering the same |
| 09/26/2001 | EP1135466A2 Mammalian non-neuronal cells that are modified to store and release a neurotransmitter |
| 09/26/2001 | EP1135411A1 Methods and compositions for treating disorders involving excitotoxicity |
| 09/26/2001 | EP1135406A1 Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
| 09/26/2001 | EP1135389A1 1,4-diazabicyclo 3.2.2]nonane derivatives, their preparation and therapeutic application |
| 09/26/2001 | EP1135384A1 Process for the production of paroxetine hydrochloride propan-2-ol solvate |
| 09/26/2001 | EP1135383A1 Mixed paroxetine propan-2-ol solvates |
| 09/26/2001 | EP1135382A1 Method of producing paroxetine hydrochloride |
| 09/26/2001 | EP1135381A1 Eletriptan hydrobromide monohydrate |
| 09/26/2001 | EP1135367A1 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same |
| 09/26/2001 | EP1135361A1 Therapeutic product and its use |
| 09/26/2001 | EP1135360A1 Novel 3-alkoxybenzylamine derivatives and their use as medicines for treating schizophrenia |
| 09/26/2001 | EP1135359A1 Derivatives of (-)-venlafaxine and methods of preparing and using the same |
| 09/26/2001 | EP1135358A1 Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| 09/26/2001 | EP1135168A1 Peptides carrying substances across the blood brain barrier |
| 09/26/2001 | EP1135166A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/26/2001 | EP1135157A1 Method for regulating the permeability of the blood brain barrier |
| 09/26/2001 | EP1135156A2 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 09/26/2001 | EP1135151A1 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 09/26/2001 | EP1135150A1 Self-emulsifying compositions for drugs poorly soluble in water |
| 09/26/2001 | EP1135147A2 Method for producing medicaments from plant extracts, in a solid form of administration |
| 09/26/2001 | EP1135136A1 Pharmaceutical compositions containing olanzapine-n-oxide |
| 09/26/2001 | EP1135134A1 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
| 09/26/2001 | EP1135125A1 Controlled-release dosage forms comprising zolpidem or a salt thereof |
| 09/26/2001 | EP1135123A1 Use of isatin derivatives as ion channel activating agents |
| 09/26/2001 | EP1135121A2 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
| 09/26/2001 | EP1135118A1 Dispersible compositions containing l-dopa ethyl ester |